Price Alert: Shares of Pacific of California (PACB) Trade 9.24% Higher at Midday June 23

Equities Staff  |

Pacific Biosciences of California Inc (NASDAQ: PACB) has climbed $0.45 (9.24%) and is currently sitting at $5.28, as of 12:07:03 est on June 23.

2,710,062 shares have exchanged hands.

The Company has risen 13.79% over the last 5 days and shares have fallen 15.16% over the last 30 days.

Pacific of California expects its next earnings on 2022-08-03.

For technical charts, analysis, and more on Pacific of California visit the company profile.

About Pacific Biosciences of California Inc

Pacific Biosciences of California, Inc. is empowering life scientists with highly accurate long-read sequencing. The company's innovative instruments are based on Single Molecule, Real-Time (SMRT®) Sequencing technology, which delivers a comprehensive view of genomes, transcriptomes, and epigenomes, enabling access to the full spectrum of genetic variation in any organism. Cited in thousands of peer-reviewed publications, PacBio® sequencing systems are in use by scientists around the world to drive discovery in human biomedical research, plant and animal sciences, and microbiology.

To get more information on Pacific Biosciences of California Inc and to follow the company's latest updates, you can visit the company's profile page here: Pacific Biosciences of California Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

The Best Laid Plans of Mice and Men — Part II
Why I’m Buying the 'New' Value Stocks
Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade



Market Movers

Sponsored Financial Content